Treatment of the psychiatric problems associated with fragile X syndrome

Current Opinion in Psychiatry

Volumn 28, Issue 2, 2015, Pages 107-112

  Hagerman, Randi J ^a,b   Polussa, Jonathan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fragile X syndrome; GABA agonists; mGluR5 antagonists; minocycline; omega 3; sertraline

Indexed keywords

ACAMPROSATE; ARBACLOFEN; CANNABINOID; GELATINASE B; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; MINOCYCLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAURINE;

ANXIETY; ATTENTION DEFICIT DISORDER; AUTISM; DRUG EFFICACY; ENVIRONMENTAL ENRICHMENT; FRAGILE X SYNDROME; HUMAN; HYPERACTIVITY; INTELLECTUAL IMPAIRMENT; INTERVENTION STUDY; KNOCKOUT MOUSE; MENTAL DISEASE; NONHUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; ANALOGS AND DERIVATIVES; ANIMAL; CHILD; FEMALE; MALE; MOUSE; PSYCHOLOGY;

ADULT; ANIMALS; CHILD; FEMALE; FRAGILE X SYNDROME; HUMANS; LOVASTATIN; MALE; MICE; MINOCYCLINE; SERTRALINE; TAURINE;

EID: 84922403583     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000131     Document Type: Review

References (51)

1. Hagerman RJ, Des-Portes V, Gasparini F, et al. Translating molecular advances in fragile X syndrome into therapy: a review. J Clin Psychiatry 2014; 75:e294-e307.
2. Heulens I, Suttie M, Postnov A, et al. Craniofacial characteristics of fragile X syndrome in mouse and man. Eur J Hum Genet 2013; 21:816-823.
3. Wadell P, Hagerman JR, Hessl RD. Fragile X syndrome: psychiatric manifestations, assessment and emerging therapies. Curr Psychiatry Rev 2013; 9:53-58.
4. Thurman AJ, McDuffie A, Hagerman R, Abbeduto L. Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. Res Dev Disabil 2014; 35:1072-1086.
5. Sidorov MS, Auerbach BD, Bear MF. Fragile X mental retardation protein and synaptic plasticity. Mol Brain 2013; 6:15.
6. Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nature Neurosci 2013; 16:1530-1536.
7. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012; 74:285-299.
8. Pop AS, Gomez-Mancilla B, Neri G, et al. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology 2014; 231:1217-1226.
9. He CX, Portera-Cailliau C. The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience 2013; 251:120-128.
10. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 2012; 54:297-335.
11. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012; 4:152ra27.
12. Berry-Kravis EM, editor. Data from the seaside trial. 14th International Fragile X Conference. Anaheim, CA; 2014.
13. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012; 42:1377-1392.
14. Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013; 161A:1897-1903.
15. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebocontrolled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013; 34:147-155.
16. Schneider A, Leigh MJ, Adams P, et al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol 2013; 27:956-963.
17. Sidhu H, Dansie LE, Hickmott PW, et al. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci 2014; 34:9867-9879.
18. Osterweil EK, Chuang SC, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013; 77:243-250.
19. Caku A, Pellerin D, Bouvier P, et al. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A 2014; 164:2834-2842.
20. Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 2010; 16:2098-2102.
21. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010; 40:1412-1416.
22. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology 2013; 228:75-84.
23. Maccarrone M, Rossi S, Bari M, et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 2010; 35:1500-1509.
24. Kano M, Ohno-Shosaku T, Hashimotodani Y, et al. Endocannabinoidmediated control of synaptic transmission. Physiol Rev 2009; 89:309-380.
25. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nature Med 2013; 19:603-607.
26. Straiker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. Neurobiol Dis 2013; 56:1-5.
27. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, et al. Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 2009; 34:1011-1026.
28. Romero-Zerbo Y, Decara J, el Bekay R, et al. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res 2009; 46:224-234.
29. Pietropaolo S, Goubran MG, Joffre C, et al. Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice. Psychoneuroendocrinology 2014; 49:119-129.
30. el Bekay R, Romero-Zerbo Y, Decara J, et al. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur J Neurosci 2007; 26:3169-3180.
31. de Diego-Otero Y, Calvo-Medina R, Quintero-Navarro C, et al. A combination of ascorbic acid and alpha-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebocontrolled trial. Trials 2014; 15:345.
32. Boccuto L, Chen CF, Pittman AR, et al. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism 2013; 4:16.
33. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999; 45:287-295.
34. Indah Winarni T, Chonchaiya W, Adams E, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: a retrospective chart review. Autism Res Treatment 2012; 2012:104317.
35. Greiss-Hess L, Hagerman RJ, editors. Sertraline treatment for young children with FXS: preliminary findings. 14th International Fragile X Conference. Anaheim, CA; 2014.
36. Erickson CA, Ray B, Maloney B, et al. Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndromeassociated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res 2014.
37. Kitaichi Y, Inoue T, Nakagawa S, et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010; 647:90-96.
38. Taler M, Miron O, Gil-Ad I,Weizman A.Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett 2013; 550:93-97.
39. Oddi D, Subashi E, Middei S, et al. Early social enrichment rescues adult behavioral and brain abnormalities in a mouse model of fragile X syndrome. Neuropsychopharmacology 2014.
40. Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci USA 2005; 102:11557-11562.
41. Estes A, Vismara L, Mercado C, et al. The impact of parent-delivered intervention on parents of very young children with autism. J Autism Dev Disord 2014; 44:353-365.
42. Lim CS, Hoang ET, Viar KE, et al. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev 2014; 28:273-289.
43. Seese RR, Babayan AH, Katz AM, et al. LTP induction translocates cortactin at distant synapses in wild-type but not Fmr1 knock-out mice. J Neurosci 2012; 32:7403-7413.
44. Hu H, Qin Y, Bochorishvili G, et al. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 2008; 28:7847-7862.
45. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123:378-390.
46. Seese RR, Wang K, Yao YQ, et al. Spaced training rescues memory and ERK1/2 signaling in fragile X syndrome model mice. Proc Natl Acad Sci USA 2014.
47. Hare EB, Hagerman RJ, Lozano R. Targeted treatments in fragile X syndrome. Expert Opin Orphan Drugs 2014; 2:531-543.
48. Lozano R, Hare EB, Hagerman RJ. Treatment of fragile X syndrome and fragile X-associated disorders. In: Hagerman RJ, Hendren RL, editors. Treatment of neurodevelopmental disorders: targeting neurobiological mechanisms. New York: Oxford University Press; 2014. pp. 215-238.
49. Au J, Berkowitz-Sutherland L, Schneider A, et al. A feasibility trial of Cogmed Working Memory training in fragile X syndrome. J Pediatr Genet (in press).
50. Lemons-Chitwood K, Mundy P, Hagerman R, Carter-Ching C, editors. Reading intervention for children with FXS. 14th International Fragile X Conference. Anaheim, CA; 2014.
51. Hagerman RJ, Hendren RL, editors. Treatment of neurodevelopmental disorders. New York: Oxford University Press; 2014.